Childhood mental disorders consist of neurodevelopmental, emotional, and behavioral disorders that have an impact on the psychological and social well-being of the child. These disorders usually persist into adulthood. Children diagnosed with these disorders are more likely to experience a compromised developmental trajectory, with an increased need for medical and disability services.
Attention deficit hyperactivity disorder (ADHD) is the most common neurodevelopmental disorder diagnosed in childhood. It’s a complex behavioural disorder whose symptoms emerge in the developmental period of a child, before age 14. It may consist of symptoms of inattention such as difficulty sustaining attention on play and other activities, not listening when spoken to, trouble organizing, being easily distracted, and so on.
|
|
|
|
Recently in the New England Journal of Medicine (NEJM), two-phase, two promising trials, Phase 2 Trial of Anti-alpha-Synuclein Antibody in Early Parkinson’s Disease (PASADENA) and SPARK, were published.1, 2 Two monoclonal antibodies (mAbs), Prasenizumab and Cinpanemab, directed at aggregated alpha-synuclein (α-synuclein) were investigated as Parkinson’s disease-modifying therapies with a similar primary endpoint (baseline changes in the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale [MDS-UPDRS] total score). They also had a similar neuroimaging secondary endpoint, i.e., single-photon-emission computed tomography (SPECT).
|